Exhibit 99.1 Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update - First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced; Topline Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immunoinflammatory diseases, today announced its financial results for the th ...